Trials that accrue participants on the basis of genetic biomarkers are a powerful means of testing targeted drugs, but they are often complicated by the rarity of the biomarker-positive population. Umbrella trials circumvent this by testing multiple hypotheses to maximize accrual. However, bigger trials have higher chances of conflicting treatment allocations because of the coexistence of multiple actionable alterations; allocation strategies greatly affect the efficiency of enrollment and should be carefully planned on the basis of relative mutation frequencies, leveraging information from large sequencing projects.
Precision Trial Drawer, a Computational Tool to Assist Planning of Genomics-Driven Trials in Oncology / Melloni, Giorgio E.M.; Guida, Alessandro; Curigliano, Giuseppe; Botteri, Edoardo; Esposito, Angela; Kamal, Maude; Le Tourneau, Christoph; Riva, Laura; Magi, Alberto; de Maria, Ruggero; Pelicci, Piergiuseppe; Mazzarella, Luca. - In: JCO PRECISION ONCOLOGY. - ISSN 2473-4284. - ELETTRONICO. - 2:(2018), pp. 1-16. [10.1200/PO.18.00015]
Precision Trial Drawer, a Computational Tool to Assist Planning of Genomics-Driven Trials in Oncology
Magi, Alberto;
2018
Abstract
Trials that accrue participants on the basis of genetic biomarkers are a powerful means of testing targeted drugs, but they are often complicated by the rarity of the biomarker-positive population. Umbrella trials circumvent this by testing multiple hypotheses to maximize accrual. However, bigger trials have higher chances of conflicting treatment allocations because of the coexistence of multiple actionable alterations; allocation strategies greatly affect the efficiency of enrollment and should be carefully planned on the basis of relative mutation frequencies, leveraging information from large sequencing projects.I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.